Abstract: Pulse cyclophosphamide (PCP) is a well established method for the treatment of lupus nephritis. PCP seems to produce better results, and lesser side effects, than oral cytotoxic drugs. We present here, our experience with this method, in 51 patients. All patients had a WHO type IV histological lesion, on light microscopy. Proteinuria, hematuria, leucocyturia, casts, BUN, creatinine, and blood pressure were measured before starting PCP and after each one. The first ...
Abstract: SLE is not a rare disease in Iran. In the past 14 years, we have seen 503 cases. Renal manifestations were discovered in 317 of them (63%). The female ratio was 87%. All of them had proteinuria, but only 50% had a proteinuria superior to 500 mg per 24 hours. 60% had hematuria, 45% leucocyturia, and 42% had urinary casts. Serum creatinine was elevated in 16% of patients. Arterial hyper-tension ...
Abstract: Behcet's Disease (BD) is rather frequent in Iran. Near 200 new cases are seen every year, and this rate is going up every year. Ophthalmological manifestations are frequent (71%). Anterior uveitis (AU) is seen in 63% of patients. It is characterized by flare and cells in the anterior chamber. Hypopion, the classic lesion of the anterior chamber is transient and rarely seen in ophthalmologic examination. The AU progresses by successive ...
Abstract: Pulse cyclophosphamide (PCP) is a well established method for the treatment of lupus nephritis. PCP seems to produce better results, and lesser side effects, than oral cytotoxic drugs. We present here, our experience with this method, in 51 patients. All patients had a WHO type IV histological lesion, on light microscopy. Proteinuria, hematuria, leucocyturia, casts, BUN, creatinine, and blood pressure were measured before starting PCP and after each one. The first ...
Abstract: PCP as lg/m2/body surface was given once per month, with 0.5 mg prednisolone/kg/day, to 155 patients with sever posterior uveitis (PU) and/ or retinal vasculitis (RV). A Disease Activity Index (DAI), based upon the inflammatory state of the eye, was calculated for each section of each eye before the first PCP and then after each PCP. When a remission was obtained the gap between PCP was increased gradually to 2, ...
Abstract: Systemic Lupus Erythematosus (SLE) is not a rare disease in Iran. In the past 13 years, we have seen 503 cases, with the following characteristics. Females 87%, males 13%, mean age 23 years (SD=11.25). Clinical manifestations were as follow: General manifestation in 57% (fever 52%, fatigue 39%, lack of appetite 18%, weight loss 36%). Mucocutaneous manifestations in 80% (malar rash 67%, discoid lesions 9%, photosensitivity 45%, alopecia 9%, Raynaud's phenomenon ...
Abstract: Ophthalmologic manifestations of BD, especially posterior uveitis and retinal vasculitis are resistant to most treatments, leading to sever loss of vision. Cytotoxic drugs, especially chlorambucil and cyclophosphamide (CP) are effective in some patients. In a preliminary report to the XI EULAR Congress of Rheumatology we demonstrated the efficacy of PTCP in these lesions. PTCP was performed by perfusion of 1 g. CP per square meter of body surface in 500 ...
Abstract: PT was performed by 2 methodes: 1- Needle prick. 2-- Intra dermal injection of normal salin. 83 % of BD patients presented a positive PT. Control subjects were composed of 101 healthy person, 46 Rheumatoid Arthritis, 5 Ankylosing Spondylitis, 18 Systemic Lupus Erythematosus (SLE). 3 Sclerodermia, and 1 permatomyositis. Among them 16% presented a positive PT. Only 3% had a positive PT with both needle prick and normal salin method. ...
Abstract: Patients with sever posterior uveitis and/or retinal vasculitis, and unresponsive to oral cytatoxic drugs and/or high doses steroids, were selected for this study. Pulse cyclophosphamide (PCP) was performed by perfusion of 1 g cyclophosphalnide per square meter of body surface in 500 ml of normal saline. PCP was repeated every month after a new evaluation of the patient. 30 mg of prednisolone/day was also given. Actually 102 patients are receiving ...
Abstract: In a separate report we demonstrated that B5 cluster antigens acts as a leading factor for ocular injuries. The question is why in some patients, these antigens does not produce the same lesions. This may be due to a genetic factor(s) which determine resistance to ocular lesions. Two HLA antigens attracted our attention as possible factors. One from the class I (CW4), and the other from the class II (DQW1). DQW1 ...